Aston Sci. Raises USD 22.7 Million Series C Funding

• Attracting a total of USD 40 Million investment and being recognized for its clinical development expertise and execution capacity
• Will apply for technology evaluation in 2H for IPO listing

SEOUL, South Korea–(BUSINESS WIRE)–#AST301—Aston Sci. (CEO: Hun Jung, Dr. Harry Hunwoo Shin) announced the completion of the Series C funding at a scale of USD 22.7 million in December last year. Aston Sci. is a clinical-stage biopharmaceutical company based on a pipeline portfolio of innovative medicines with a focus on therapeutic cancer vaccines.

With a compelling safety profile and treatment effects to prevent cancer recurrence after a standard treatment, therapeutic cancer vaccines are drawing attention from the high-risk patients with early-stage cancer in the global market.

In addition to the five existing investors including Timefolio Asset Management and Mirae Asset Venture Investment, four new investors participated in the Series C funding round. Including the Series C funding, Aston Sci. has attracted investment at a scale of USD 40 million in total. The raised fund will be used in global clinical development and drug discovery projects.

�The funding has been made possible as investors highly evaluated the clinical development expertise and execution capacity of Aston Sci. despite recent uncertainty toward biotech sector in investment markets,” said Dr. Harry Shin. “Starting with the phase 2 randomized-controlled clinical trial (multinational study in the U.S., Australia, and Taiwan) for AST-301 expected to take place during the second quarter of this year, the value of each pipeline will continuously increase.”

Aston Sci. has secured ten pipelines in preclinical and clinical stages including two clinical stage therapeutic cancer vaccines for which the study results were presented at the 2021 ASCO Annual Meeting and the 2021 SITC Annual Meeting. The company plans to develop a stable new drug development portfolio by expanding its pipeline to 15 drugs in four clinical fields by 2030. In particular, for AST-301, a phase 2 RCT program is soon to commence in Australia, the U.S., and Taiwan, targeting HER2 +1/+2 breast cancer patients.

Aston Sci. decided to list on the KOSDAQ in order to facilitate its clinical and business development, and the company will prepare for its listing by applying for a technology evaluation in the second half of this year.

About Aston Sci. Inc.

Aston Sci. is a clinical-stage biopharmaceutical company. It is highly regarded in the industry for its active pipelines and portfolio composition that mainly focus on the clinical development of innovative medicines in oncology, immunology, and geriatrics. Aston Sci. is headquartered in Seoul, South Korea, and Aston Sci. USA, Inc. is located in Seattle.

Contacts

Aston Sci. Inc.

Kevin KP Jang

External Communications Manager

kp.jang@astonsci.com